ArticleNaunyn-Schmiedeberg's archives of pharmacology2015
Effects of Tanshinone IIA on osteogenic differentiation of mouse bone marrow mesenchymal stem cells.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- The Skeletal Effects of Tanshinones: A Review.Molecules (Basel, Switzerland) · 2021Pooled it
- Pharmacological Effects and Mechanisms of Tanshinone IIA in Bone Injury Repair.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Development of optimized differentiation media for murine bone marrow multipotent mesenchymal stromal cells.Histochemistry and cell biology · 2025Article
- Mechanism of action of Salvia miltiorrhiza on avascular necrosis of the femoral head determined by integrated network pharmacology and molecular dynamics simulation.Scientific reports · 2024Article
- Local Application of Tanshinone IIA protects mesenchymal stem cells from apoptosis and promotes fracture healing in ovariectomized mice.Journal of orthopaedic surgery and research · 2024Article
- Research Progress on Regulation of Immune Response by Tanshinones and Salvianolic Acids of Danshen (Molecules (Basel, Switzerland) · 2024Review
- Salvia miltiorrhiza in osteoporosis: a review of its phytochemistry, traditional clinical uses and preclinical studies (2014-2024).Frontiers in pharmacology · 2024Review
- Expanding the therapeutic potential ofFrontiers in pharmacology · 2023Review
- Effect of Active Ingredients of Chinese Herbal Medicine on the Rejuvenation of Healthy Aging: Focus on Stem Cells.Evidence-based complementary and alternative medicine : eCAM · 2020Review
- Recruitment of Mesenchymal Stem Cells to Damaged Sites by Plant-Derived Components.Frontiers in cell and developmental biology · 2020Review
- miR‑204 inhibits the osteogenic differentiation of mesenchymal stem cells by targeting bone morphogenetic protein 2.Molecular medicine reports · 2020Article
- Effects of various antimicrobial agents on multi-directional differentiation potential of bone marrow-derived mesenchymal stem cells.World journal of stem cells · 2019Review
- Comparative Study onStem cells international · 2018Article
- Easy-to-use strategy for reference gene selection in quantitative real-time PCR experiments.Naunyn-Schmiedeberg's archives of pharmacology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tanshinone IIA (TSA) is a lipophilic diterpene purified from the Chinese herb Danshen, which exhibits potent antioxidant and anti-inflammatory properties. Effect of TSA remains largely uninvestigated on the osteogenic differentiation of bone marrow mesenchymal stem cells (BM-MSCs), which are widely used in cell-based therapy of bone diseases. In the present study, both ALP activity at day 7 and calcium content at day 24 were upregulated during the osteogenesis of mouse BM-MSCs treated with TSA (1 and 5 μM), demonstrating that it promoted the osteogenesis at both early and late stages. We found that TSA promoted osteogenesis and inhibited osteoclastogenesis, evident by RT-PCR analysis of osteogenic marker gene expressions. However, osteogenesis was inhibited by TSA at 20 μM. We further revealed that TSA (1 and 5 μM) upregulated BMP and Wnt signaling. Co-treatment with Wnt inhibitor DKK-1 or BMP inhibitor noggin significantly decreased the TSA-promoted osteogenesis, indicating that upregulation of BMP and Wnt signaling plays a significant role and contributes to the TSA-promoted osteogenesis. Of clinical interest, our study suggests TSA as a promising therapeutic strategy during implantation of BM-MSCs for a more effective treatment of bone diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.